The IDIOM study is designed to compare how a diet with moderate caloric restriction, alone or with long-acting insulin, affects areas of the brain’s dopamine system that are involved in food intake, reward and the sense of pleasure people get from eating.

Vanderbilt’s Eskind Diabetes Clinic has been selected to examine the ability of the drug abatacept to prevent type 1 diabetes (T1D). As part of the TrialNet consortium, Vanderbilt will be one of 14 North American sites observing the effects of the drug in people at high risk to develop T1D.

Vanderbilt researchers propose guidelines for defining patient retention in clinical studies – an important parameter that affects study conclusions and program evaluations.

The Vanderbilt Breast Center is piloting new measures to ensure continuity of care and timely insurance preauthorization as patients come off grant-sponsored clinical trial protocols and begin or resume standard care.

ResearchMatch, a national on-line volunteer recruitment service hosted by Vanderbilt University, has launched a sub-registry for autism spectrum disorders (ASD) to increase the participation of children and adults with autism in clinical research studies.

A type I diabetes prevention study that is part of the TrialNet program at Vanderbilt is now enrolling children as young as 8 years old.

A newer version of an old class of blood pressure lowering drugs may offer advantages for obese patients with metabolic syndrome.